Home — The Jenner Institute

Oxford malaria vaccine receives regulatory clearance for use in Burkina Faso

The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Burkina Faso by the country’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).

African Phase I HIV vaccine trial shows encouraging preliminary results

The clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully. Preliminary analysis of the trial results demonstrates the induction of high frequencies of broadly specific T cells that recognise functionally conserved regions on HIV-1 and are therefore more protective.

Jenner Institute DPhil Symposium

The Jenner Institute DPhil Symposium on 23 June 2023 brought together over 80 DPhil Students, Research Assistants, Technicians and Apprentices across the Nuffield Department of Medicine to network and share their research and career aspirations.

Oxford malaria vaccine receives regulatory clearance for use in Ghana

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.

Prof Adrian Hill, Lakshmi Mittal & Family Professor Of Vaccinology and Director of the Jenner Institute; and Dr César López-Camacho, Senior Researcher and Group Leader for mRNA technologies, with Ms Josefa González-Blanco at the Jenner Institute.

Mexican Ambassador visits Jenner Institute

The Mexican Ambassador to the United Kingdom, Her Excellency Ms Josefa González-Blanco Ortiz Mena, was given a tour and met with representatives of the Jenner Institute.

Romain Guyon awarded 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

Illustration showing how the Ebola virus looks under a microscope

Ebola vaccine to begin human trials

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.

History of the COVID-19 vaccine

The Oxford / AstraZeneca COVID-19 vaccine is estimated to have saved more than six million lives – more than any other COVID vaccine, during the first year of use.

Find out more

Support us

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

Make a gift

Publications

Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.
Journal article

Joe CCD. et al, (2023), Biotechnol Bioeng
Aging unconventionally: γδ T cells, iNKT cells, and MAIT cells in aging.
Journal article

Kurioka A. and Klenerman P., (2023), Seminars in immunology, 69
Single-cell diversity and functional plasticity of human MAIT cells.
Journal article

(2023), Nature immunology, 24, 1409 - 1410

More publications

Seminars

SpyVector; a modular capsid decoration platform to boost adenovirus vaccine-induced humoral immunity

Thursday, 23 November 2023, 1pm to 2pm

More seminars

Cookies on this website

Oxford malaria vaccine receives regulatory clearance for use in Burkina Faso

History of the COVID-19 vaccine

Support us

Publications

Seminars

SpyVector; a modular capsid decoration platform to boost adenovirus vaccine-induced humoral immunity

Follow us